Completed PHASE1 INTERVENTIONAL 2-arm NCT04219865

Safety, Tolerance and Pharmacokinetics Study of Compound Edaravone Injection

Study on the Safety, Tolerance and Pharmacokinetics of Single-dose, Increasing and Loading Dose and Maintenance Dose Sequential Intravenous Infusion of Compound Edaravone Injection in Chinese Healthy Volunteers

Sponsor: Nanjing Yoko Biomedical Co., Ltd.

Conditions Pharmacokinetics

Interventions Group 1: Compound Edaravone/Placebo Injection Group 2: Compound Edaravone/Placebo Injection Group 3: Compound Edaravone/Placebo Injection Group 4: Compound Edaravone/Placebo Injection Group 5: Compound Edaravone/Placebo Injection

Updated 5 times since 2020 Last updated: Mar 19, 2021 Started: Jun 5, 2019 Primary completion: Aug 16, 2019 Completion: Aug 16, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04219865, this PHASE1 trial focuses on Pharmacokinetics and remains completed. Sponsored by Nanjing Yoko Biomedical Co., Ltd., it has been updated 5 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Apr 2021 — Jul 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jan 2021 — Apr 2021 [monthly]

Active Not Recruiting PHASE1
Feb 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1

First recorded

Jun 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nanjing Yoko Biomedical Co., Ltd.

Data source: Nanjing Yoko Biomedical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China